Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Dewsnup, D. H.    Stevens, D. A.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Is It Ever Safe To Stop Azole Therapy for Coccidioides immitis Meningitis?

Daniel H. Dewsnup, DO, MS; John N. Galgiani, MD; J. Richard Graybill, MD; Manuel Diaz, MD; Adrian Rendon, MD; Gretchen A. Cloud, MS; and David A. Stevens, MD

1 February 1996 | Volume 124 Issue 3 | Pages 305-310

Objective: To determine 1) whether patients with coccidioidal meningitis who had achieved remission with oral azole therapy were cured and 2) when oral azole therapy could be discontinued in these patients.

Design: Data were gathered on patients with coccidioidal meningitis who had successfully responded to azole therapy in previous clinical trials.

Setting: Referral centers, including university, county, and veterans' hospitals and clinics.

Patients: 18 patients in whom azole therapy for meningitis had been discontinued, usually because of a presumption of cure.

Main Outcome Measures: Clinical and cerebrospinal fluid relapse.

Results: 14 of 18 patients (78% [95% CI, 52% to 94%]) had relapse with disseminated disease after discontinuation of therapy, for a total of 1 nonmeningeal and 15 meningeal relapses to date. Relapse occurred both soon and late (range, 0.5 to 30 months) after therapy was discontinued. The characteristics of patients who did not have relapse, including the particular azole used, the duration of therapy, the reason therapy was discontinued, and the cerebrospinal fluid indices before discontinuation, were similar to the characteristics of patients who had relapse. Relapse had serious consequences in some patients; 3 patients died.

Conclusion: Our data suggest 1) that disease is only suppressed in patients with meningitis who achieve remission while receiving azole therapy and 2) that discontinuing azole therapy is unsafe. The alternative is lifelong treatment with azoles; this appears to be acceptable, because toxicity is uncommon with triazole therapy, even long-term triazole therapy.

Author and Article Information

From Santa Clara Valley Medical Center and The California Institute for Medical Research, San Jose, California; Stanford University School of Medicine, Standford, California; The National Institute of Allergy and Infectious Diseases Mycoses Study Group, Bethesda, Maryland; Veterans Affairs Medical Center and University of Arizona, Tucson, Arizona; Audie Murphy Memorial Veterans Hospital and University of Texas Health Science Center, San Antonio, Texas; Universidad Autonoma de Nuevo Leon and Hospital Universitario, Monterrey, Mexico; and University of Alabama, Birmingham, Alabama.
Acknowledgments: The authors thank Thomas G. Evans, MD, Stephanie Eyherabide, RN, L. Thomas Fife, MD, Jean Higgs, RN, Bernard E. Levine, MD, John F. Rothrock, MD, Ziad Shehab, MD, Martha H. Tanner, MD, Judy Tenopir, Idelle Weisman, MD, and others who provided helpful information.
Grant Support: In part by the National Institute of Allergy and Infectious Diseases (Contract N01-AI-15082); The Office of Veterans Affairs; Janssen Research Foundation, Titusville, New Jersey; Pfizer Central Research and Pfizer International, Groton, Connecticut and New York, New York; and the Bank of Stockton, Stockton, California.
Requests for Reprints: David A. Stevens, MD, Department of Medicine, Santa Clara Valley Medical Center, 751 South Bascom Avenue, San Jose, CA 95128-2699.
Current Author Addresses: Dr. Dewsnup: Infectious Disease/HIV Unit, California Medical Facility, PO Box 2000, Vacaville, CA 95696.

This article has been cited by other articles:

				J. Capilla, K. V. Clemons, R. A. Sobel, and D. A. Stevens Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis J. Antimicrob. Chemother., September 1, 2007; 60(3): 673 - 676. [Abstract] [Full Text] [PDF]

				P. Kamberi, R. A. Sobel, K. V. Clemons, A. Waldvogel, J. M. Striebel, P. L. Williams, and D. A. Stevens Comparison of Itraconazole and Fluconazole Treatments in a Murine Model of Coccidioidal Meningitis Antimicrob. Agents Chemother., March 1, 2007; 51(3): 998 - 1003. [Abstract] [Full Text] [PDF]

				L. A. Proia and A. R. Tenorio Successful Use of Voriconazole for Treatment of Coccidioides Meningitis Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2341 - 2341. [Full Text] [PDF]

				K. V. Clemons, R. A. Sobel, P. L. Williams, D. Pappagianis, and D. A. Stevens Efficacy of Intravenous Liposomal Amphotericin B (AmBisome) against Coccidioidal Meningitis in Rabbits Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2420 - 2426. [Abstract] [Full Text] [PDF]

				K. V. Clemons, R. A. Sobel, P. L. Williams, and D. A. Stevens Comparative Toxicities and Pharmacokinetics of Intrathecal Lipid (Amphotericin B Colloidal Dispersion) and Conventional Deoxycholate Formulations of Amphotericin B in Rabbits Antimicrob. Agents Chemother., February 1, 2001; 45(2): 612 - 615. [Abstract] [Full Text]

				K. N. Sorensen, R. A. Sobel, K. V. Clemons, L. Calderon, K. J. Howell, P. R. Irani, D. Pappagianis, P. L. Williams, and D. A. Stevens Comparative Efficacies of Terbinafine and Fluconazole in Treatment of Experimental Coccidioidal Meningitis in a Rabbit Model Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3087 - 3091. [Abstract] [Full Text]

				K. V. Clemons and D. A. Stevens Efficacies of Sordarin Derivatives GM193663, GM211676, and GM237354 in a Murine Model of Systemic Coccidioidomycosis Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1874 - 1877. [Abstract] [Full Text]

				K. N. Sorensen, R. A. Sobel, K. V. Clemons, D. Pappagianis, D. A. Stevens, and P. L. Williams Comparison of Fluconazole and Itraconazole in a Rabbit Model of Coccidioidal Meningitis Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1512 - 1517. [Abstract] [Full Text]

				O. Lortholary, D. W. Denning, and B. Dupont Endemic mycoses: a treatment update J. Antimicrob. Chemother., March 1, 1999; 43(3): 321 - 331. [Abstract] [Full Text] [PDF]

				J. N. Galgiani Coccidioidomycosis: A Regional Disease of National Importance: Rethinking Approaches for Control Ann Intern Med, February 16, 1999; 130(4_Part_1): 293 - 300. [Abstract] [Full Text] [PDF]

				AZOLES FOR COCCIDIOIDES MENINGITIS Journal Watch (General), February 16, 1996; 1996(216): 5 - 5. [Full Text]